会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 95. 发明授权
    • Dimple-forming burnishing tool
    • 凹痕成型抛光工具
    • US08931320B2
    • 2015-01-13
    • US13326968
    • 2011-12-15
    • Shinya MiyauchiTetsuya SuzukiMasaru Futamura
    • Shinya MiyauchiTetsuya SuzukiMasaru Futamura
    • B21D17/04B21D1/02B21D3/02B21D1/08B21C37/30B24B39/02
    • B24B39/023Y10T29/47
    • A dimple-forming burnishing tool allowing easy adjustment of a dimple shape is provided. The dimple-forming burnishing tool has a mandrel attached on a rear-end side thereof to a processing machine for rotation, and a cylindrical frame rotatably externally fitted on a tip side of the mandrel and holding a rolling element and a pressing element that are driven by rotation of the mandrel, for forming dimples in an inner surface of a workpiece by rotating the mandrel with the frame disposed inside the inner surface of the workpiece. In the dimple-forming burnishing tool, the mandrel includes a dimple adjusting mechanism. The dimple adjusting mechanism includes: a rolling element rotating portion causing the rolling element to rotate without moving in and out radially of the frame; and a pressing element in-and-out rotating portion causing the pressing element to rotate while moving in and out radially of the frame.
    • 提供了一种容易调节凹坑形状的凹坑成形抛光工具。 凹坑成形抛光工具在其后端侧具有安装在旋转用加工机上的心轴,以及可旋转地外嵌于心轴的前端侧的圆筒状框架,保持被驱动的滚动体和按压元件 通过心轴的旋转,通过使心轴与设置在工件的内表面内的框架旋转来在工件的内表面中形成凹坑。 在凹坑形成抛光工具中,心轴包括凹坑调节机构。 凹坑调节机构包括:滚动元件旋转部,其使滚动元件旋转而不在框架的径向移动; 以及按压元件进出旋转部分,使得按压元件在框架的径向移动进入和移出的同时旋转。
    • 98. 发明申请
    • METHOD FOR DETERMINATION OF SENSITIVITY TO ANTI-CANCER AGENT
    • 用于确定抗癌剂敏感性的方法
    • US20120214831A1
    • 2012-08-23
    • US13504985
    • 2010-10-29
    • Yusuke TanigawaraSayo SuzukiYusuke IkomaAkito NishimutaTetsuya SuzukiShinji Sugimoto
    • Yusuke TanigawaraSayo SuzukiYusuke IkomaAkito NishimutaTetsuya SuzukiShinji Sugimoto
    • A61K31/505A61P35/00A61K31/282C40B30/10G01N33/53
    • A61K31/513A61K31/555G01N30/7233G01N33/574G01N33/57419G01N2333/4727G01N2800/52
    • To provide a marker for determining sensitivity of a patient to an anti-cancer agent, and novel cancer therapeutic means employing the marker.The marker for determining sensitivity to an anti-cancer agent is formed of a protein selected from the group consisting of a protein or a fragment thereof which is detected as a peak at m/z of 5,300 to 5,400, a protein or a fragment thereof which is detected as a peak at m/z of 6,130 to 6,230, a protein or a fragment thereof which is detected as a peak at m/z of 7,000 to 7,080, a protein or a fragment thereof which is detected as a peak at m/z of 7,840 to 7,920, a protein or a fragment thereof which is detected as a peak at m/z of 8,920 to 9,000, a protein or a fragment thereof which is detected as a peak at m/z of 12,440 to 12,560, a protein or a fragment thereof which is detected as a peak at m/z of 17,100 to 17,270, a protein or a fragment thereof which is detected as a peak at m/z of 18,290 to 18,470, a protein or a fragment thereof which is detected as a peak at m/z of 24,660 to 24,750, a protein or a fragment thereof which is detected as a peak at m/z of 35,980 to 36,290, a protein or a fragment thereof which is detected as a peak at m/z of 8,650 to 8,750, a protein or a fragment thereof which is detected as a peak at m/z of 9,100 to 9,200, a protein or a fragment thereof which is detected as a peak at m/z of 11,760 to 11,890, and S100A10, the peaks being determined by means of a mass spectrometer.
    • 提供用于确定患者对抗癌剂的敏感性的标记物,以及采用该标记物的新型癌症治疗方法。 用于确定对抗癌剂的敏感性的标记物由选自蛋白质或其片段的蛋白质或其片段的蛋白质或其片段形成,所述蛋白质或其片段以m / z为峰值检测为5,300至5,400,其蛋白质或其片段 被检测为m / z为6,130至6,230的峰,其蛋白质或其片段被检测为m / z为7,000至7,080的峰,其蛋白质或其片段被检测为m / 检测为m / z为8,920至9,000的峰的蛋白质或其片段为7,840至7,920,其蛋白质或其片段被检测为m / z为12,440至12,560的峰,蛋白质或其片段 或其片段,其检测为m / z为17,100至17,270的峰,其蛋白质或其片段被检测为m / z为18,290至18,470的峰,其蛋白质或其片段被检测为 m / z的峰值为24,660〜24,750,是以m / z为35,980〜36,290的峰值检测出的蛋白质或其片段, 被检测为m / z为8,650〜8,750的峰的ein或其片段,检测为m / z为9,100〜9,200的峰的蛋白质或其片段,检测到的蛋白质或其片段 作为m / z为11,760〜11,890的峰,S100A10为峰,通过质谱仪测定。
    • 99. 发明申请
    • MEDICAL INSTRUMENT AND METAL PRODUCT
    • 医疗器械及金属制品
    • US20120177936A1
    • 2012-07-12
    • US13390194
    • 2010-08-12
    • Tetsuya SuzukiKazunori Murakami
    • Tetsuya SuzukiKazunori Murakami
    • B32B15/04A61B17/00
    • A61L31/088A61F2/88A61F2/915A61F2310/0058A61L31/022A61L2420/08C23C16/26Y10T428/24942Y10T428/30Y10T428/31678
    • [Object] To provide a medical instrument capable of more effectively inhibiting a cracking and separation than conventional ones.[Solution Means] A stent comprising a substrate layer 10 of which at least the surface is composed of a metal material, a carbon compound layer 12 that is formed so as to coat the surface of the substrate layer 10 and that contains at least one metal element, a first DLC layer 14 that is formed so as to coat the surface of the carbon compound layer 12 and that is free of fluorine, and a second DLC layer 16 that is formed so as to coat the surface of the first DLC layer 14 and that contains fluorine. The stent being constituted to satisfy the relationship defined by the expression of “A1>A2>A3”, wherein A1 is a surface free energy of the carbon compound layer 12, A2 is a surface free energy of the first DLC layer 14, and A3 is a surface free energy of the second DLC layer 16.
    • 本发明提供能够比现有技术更有效地抑制裂解和分离的医疗器械。 [解决方案]一种支架,其包括基材层10,其至少表面由金属材料构成,碳化合物层12形成为涂覆基材层10的表面并且含有至少一种金属 元素,形成为涂覆碳化合物层12的表面并且不含氟的第一DLC层14和形成为涂覆第一DLC层14的表面的第二DLC层16 并含有氟。 支架构成为满足由“A1> A2> A3”的表达式定义的关系,其中A1是碳化合物层12的表面自由能,A2是第一DLC层14的表面自由能,而A3 是第二DLC层16的表面自由能。